GeneSight Cost in 2026: Pricing, Insurance, and Alternatives
7 min read · Last updated: March 2026 · DecodeMyBio Editorial Team
GeneSight is one of the most widely used pharmacogenomic tests for psychiatric medications. This page breaks down GeneSight's current pricing, insurance coverage — including the 2025 UnitedHealthcare policy change — and how the cost compares to Genomind and raw data analysis alternatives. For a consolidated overview that also covers evidence and alternatives, see our independent GeneSight cost, insurance & alternatives guide.
Already have DNA data from 23andMe or AncestryDNA?
You can get pharmacogenomic analysis using data you already own — no new test, no provider order, no insurance billing. DecodeMyBio maps your raw data to published CPIC clinical guidelines across 19 genes and 150+ drug-gene interactions.
GeneSight Pricing Summary
GeneSight is manufactured by Myriad Genetics. The test analyzes 15 genes covering over 60 psychotropic medications and requires a provider order. According to genesight.com:1
| Payer Type | Typical Out-of-Pocket Cost |
|---|---|
| Self-pay (no insurance) | $3301 |
| Medicare Part B | $0 typical1 |
| Medicaid | $0 typical1 |
| Commercial insurance | Varies by plan — check with insurer |
1 GeneSight (genesight.com/cost/): "All patients are eligible for the reduced self-pay option of $330." Medicare Part B: "$0 is the typical out-of-pocket cost." Medicaid: "$0 is the typical out-of-pocket cost."
UnitedHealthcare Policy Change (2025)
On November 4, 2024, Myriad Genetics disclosed that UnitedHealthcare (UHC) had updated its medical policy for multi-gene pharmacogenetic testing panels, effective January 1, 2025.2
In a follow-up statement on December 10, 2024, Myriad Genetics said it was "in active discussions with UnitedHealthcare regarding coverage of pharmacogenetic testing" and expected to provide "further clarity by year-end."3
What Changed
- Affected plans: UHC commercial and individual exchange plans2
- Not affected: Medicare Advantage and managed Medicaid plans were excluded from this policy change2
- Scope: The policy applies to multi-gene pharmacogenetic panels — not only GeneSight, but any multi-gene PGx test billed to UHC commercial plans
This change does not eliminate GeneSight as an option. Patients on affected UHC plans may still take the test at the $330 self-pay rate. Patients on Medicare Part B, Medicaid, or non-UHC commercial plans were not affected.
How GeneSight Compares on Cost
Information sourced from each company's public materials as of March 2026. Verify current details directly with each provider.
| Feature | GeneSight | Genomind PGx Express | DecodeMyBio (raw data) |
|---|---|---|---|
| Self-pay cost | $3301 | $5994 | $49 (Medication Safety) or $59 (Psychiatric) |
| Medicare Part B | $0 typical1 | $0 if criteria met4 | N/A |
| Provider order required | Yes | Yes | No |
| Insurance billing | Yes | Yes | No |
| Genes tested | 155 | 266 | 19 |
| Medications covered | Over 60 psychotropic5 | 130+ neuropsychiatric7 | 100+ across 3 reports |
| Guideline basis | Proprietary algorithm | Proprietary | CPIC published guidelines |
| Uses existing DNA data | No | No | Yes |
4 Genomind (genomind.com/cost-and-coverage/): "$599 one-time payment when registering." Medicare Part B: "$0 out of pocket if coverage criteria are met."
5 GeneSight (genesight.com/product/): 9 PK genes + 5 PD genes + COMT. "over 60 mental health medications."
6 Genomind (genomind.com/solutions/pharmacogenetic-testing/genes/): "Pharmacogenetic testing with Genomind analyzes 26 selected genes."
7 Genomind (genomind.com/solutions/pharmacogenetic-testing/): "analyzing 26 genes, offering insights into 130+ neuropsychiatric medications."
Who Should Consider Each Option
Cost is one factor in choosing a pharmacogenomic testing approach. Here is how the three categories differ in practice:
- GeneSight or Genomind — best suited when your prescriber wants a provider-ordered test with clinical laboratory analysis, particularly if covered by insurance. Both require a provider order and produce a clinician-facing report.
- Raw data analysis — an option if you already have consumer DNA data (23andMe, AncestryDNA) and want informational pharmacogenomic insights mapped to published CPIC guidelines. No provider order or insurance billing required.
Consumer genotyping arrays cover a defined set of variants and have known limitations — see our limitations page and methodology for details. For high-stakes prescribing decisions, a provider-ordered test may be appropriate.
See what pharmacogenomic analysis looks like with your existing DNA data. Upload your raw data file from 23andMe or AncestryDNA to get your metabolizer phenotypes mapped to CPIC guidelines across 19 genes and 150+ drug-gene interactions.
Upload your data · View a sample report · GeneSight vs Genomind comparison
Frequently Asked Questions
How much does GeneSight cost without insurance?
GeneSight's self-pay cost is $330. According to genesight.com, "All patients are eligible for the reduced self-pay option of $330."1 This is a one-time fee for the test, including the cheek swab kit, laboratory analysis, and clinician report.
Does Medicare cover GeneSight?
Yes, Medicare Part B typically covers GeneSight at $0 out-of-pocket. GeneSight states that "$0 is the typical out-of-pocket cost" for Medicare Part B beneficiaries.1 Coverage applies when the test is ordered by an eligible provider for a qualifying indication.
Does UnitedHealthcare cover GeneSight?
UnitedHealthcare updated its medical policy for multi-gene pharmacogenetic panels effective January 1, 2025.2 According to Myriad Genetics, this change applies to UHC commercial and individual exchange plans. Medicare Advantage and managed Medicaid plans were not affected.2 Patients should verify current coverage directly with UHC.
Is there a cheaper alternative to GeneSight?
If you already have raw DNA data from 23andMe, AncestryDNA, or another consumer test, raw data analysis services can provide pharmacogenomic insights at lower cost. DecodeMyBio's Medication Safety report costs $49 and the Psychiatric report costs $59 — both are one-time fees with no insurance billing. This is informational analysis mapped to published CPIC guidelines, not a clinical diagnostic test.
References
- GeneSight Pricing — genesight.com/cost/. genesight.com
- Myriad Genetics on UHC Policy — GlobeNewsWire, November 4, 2024. globenewswire.com
- Myriad Genetics UHC Update — GlobeNewsWire, December 10, 2024. globenewswire.com
- Genomind Pricing — genomind.com/cost-and-coverage/. genomind.com
- GeneSight Product Information — genesight.com/product/. genesight.com
- Genomind Gene List — genomind.com/solutions/pharmacogenetic-testing/genes/. genomind.com
- Genomind Professional PGx Express — genomind.com/solutions/pharmacogenetic-testing/. genomind.com